Mylan Price Target Increased to $31.00 by Analysts at RBC Capital (MYL)

Mylan (NYSE: MYL) had its price target increased by RBC Capital from $29.00 to $31.00 in a research note released on Wednesday morning. They currently have an outperform rating on the stock.

A number of other analysts have also recently weighed in on MYL. Analysts at Canaccord Genuity downgraded shares of Mylan from a buy rating to a hold rating in a research note to investors on Monday. They now have a $33.00 price target on the stock. Separately, analysts at Bank of America reiterated a buy rating on shares of Mylan in a research note to investors on Monday, March 4th. They now have a $34.00 price target on the stock, up previously from $33.00. Finally, analysts at Argus raised their price target on shares of Mylan from $32.00 to $35.00 in a research note to investors on Monday, March 4th. They now have a buy rating on the stock.

Eleven research analysts have rated the stock with a buy rating, two have given an overweight rating, seven have assigned a hold rating, and one has assigned an underweight rating to the company’s stock. The company presently has an average rating of overweight and an average target price of $32.93.

Mylan (NYSE: MYL) traded down 1.16% on Wednesday, hitting $30.65. Mylan has a 52-week low of $20.21 and a 52-week high of $31.22. The stock’s 50-day moving average is currently $29.31. The company has a market cap of $12.124 billion and a price-to-earnings ratio of 20.40.

Mylan, Inc. develops and markets generics along with a number of proprietary drugs. The Company’s product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson’s disease, and a wound care product to treat diabetic foot ulcers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.